The Canadian Network for Mood and Anxiety Treatments and the International College of Obsessive-Compulsive Spectrum Disorders have teamed up to provide a comprehensive new guideline for the management of patients with obsessive-compulsive disorder.
All of the following statements about the new product Dyanavel XR (amphetamine 5 mg, 10 mg, 15 mg and 20 mg extended-release tablets) for treatment of attention deficit hyperactivity disorder are true, EXCEPT for . . .
The Canadian Network for Mood and Anxiety Treatments and the International College of Obsessive-Compulsive Spectrum Disorders have teamed up to provide a comprehensive new guideline for the management of patients with obsessive-compulsive disorder.